Current Assets
Raw materials
Vertex Pharmaceuticals Raw materials increased by 2.9% to $267.4M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.7%, from $250.5M to $267.4M. Over 5 years (FY 2020 to FY 2025), Raw materials shows an upward trend with a 41.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2015
Last reportedQ1 2026May 5, 2026
Parent metricInventories
Metric ID:
inv_raw_materialsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $47.74M | $45.99M | $42.4M | $42.2M | $30.4M | $32.2M | $38.1M | $58.1M | $71.8M | $77.5M | $78.7M | $95.7M | $112.1M | $141.1M | $252M | $250.5M | $221.4M | $278.6M | $259.8M | $267.4M |
| QoQ Change | — | -3.7% | -7.8% | -0.5% | -28.0% | +5.9% | +18.3% | +52.5% | +23.6% | +7.9% | +1.5% | +21.6% | +17.1% | +25.9% | +78.6% | -0.6% | -11.6% | +25.8% | -6.7% | +2.9% |
| YoY Change | — | — | — | — | -36.3% | -30.0% | -10.1% | +37.7% | +136.2% | +140.7% | +106.6% | +64.7% | +56.1% | +82.1% | +220.2% | +161.8% | +97.5% | +97.4% | +3.1% | +6.7% |
| % of Inventories | 14.8% | 13.8% | 12.0% | 12.5% | 8.3% | 8.3% | 8.3% | 10.9% | 11.9% | 11.3% | 10.7% | 11.8% | 12.3% | 13.1% | 20.9% | 18.4% | 14.8% | 17.1% | 15.4% | 15.1% |
| Share Change | — | -1.1pp | -1.8pp | +0.4pp | -4.2pp | +0.0pp | -0.0pp | +2.6pp | +1.0pp | -0.6pp | -0.6pp | +1.1pp | +0.5pp | +0.8pp | +7.8pp | -2.5pp | -3.7pp | +2.4pp | -1.7pp | -0.3pp |
Range$30.4M – $278.6M
CAGR+43.7%
Avg YoY Growth+70.9%
Median YoY Growth+73.4%
Raw materials at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's raw materials?
- Vertex Pharmaceuticals (VRTX) reported raw materials of $267.4M in Q1 2026.
- How has Vertex Pharmaceuticals's raw materials changed year-over-year?
- Vertex Pharmaceuticals's raw materials increased by 6.7% year-over-year, from $250.5M to $267.4M.
- What is the long-term trend for Vertex Pharmaceuticals's raw materials?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's raw materials has grown at a 41.2% compound annual growth rate (CAGR), from $46.23M to $259.8M.